TOPIC:

Abbott Laboratories

Watch breaking news videos and read news updates about Abbott Laboratories on FOXBusiness.com.

LATEST VIDEOS

Pharma to Benefit From Health-Care Reform

10/14/2009|FOX Business

Pharma to Benefit From Health-Care ReformS&P's Sam Stovall argues health-care reform will benefit pharmaceuticals by increasing customers.

Stimulus: Pass or Fail?

10/12/2009|Web Exclusive

Stimulus: Pass or Fail?We break down if the government spending plan has hit the mark or missed its target.

The Rally's Big Players

10/12/2009|Web Exclusive

The Rally's Big PlayersBarron's Mike Santoli on breaks down the players who have played the rally correctly.

Ex-CBO Director on Health-Care Costs

10/12/2009|FOX Business

Ex-CBO Director on Health-Care CostsFmr. Congressional Budget Office Director Douglas Holtz-Eakin on health-care reform's impact on the national debt.

Housing's Fake Band-Aid

09/29/2009|Web Exclusive

Housing's Fake Band-AidWe break down why the good news coming from the housing sector might not be sustainable.

Big Week for M&A, but Will it Continue?

09/29/2009|FOX Business

Big Week for M&A, but Will it Continue?Levey & Co Co-Founder Claire Gruppo on the outlook for m&a activity.

Cavuto Business Report 9-28-09

09/28/2009|FOX Business

Cavuto Business Report 9-28-09Merger mania sends stocks soaring. Meanwhile, Xerox worked out a deal to buy Affiliated Computer.

Summer Outlook for the Markets

05/26/2009|Money for Breakfast

Summer Outlook for the MarketsTim Call of The Capital Management Corp., and Dow Jones Newswires Managing Editor Neil Lipschutz on what to expect from the markets this summer.

LATEST STORIES

Abbott Laboratories Reports Positive Results on Niaspan

FOXBusiness| Markets

FOXBusiness Abbott Laboratories (ABT) announced on Monday positive results of cholesterol drug Niaspan. The company said that patients who used Niaspan along

Story|11/16/2009

Merck, Abbott Rise After Study

FOXBusiness| Markets

study of cholesterol drug Zetia that showed Zetia did not combat artery clogging as well as Niaspan, made by Abbott Laboratories (ABT). However, the study found Zetia does not worsen artery-clogging. Barbara Ryan, an analyst for Deutsche

Story|11/16/2009

Large-cap Stocks Are Market's Best Value

By Chuck Jaffe| MarketWatch| Markets

INTC) , Microsoft Corp. (MSFT) , Corning Inc. (GLW) , Raytheon Co. (RTN) , Monsanto Co. (MON) , Abbott Laboratories (ABT) , Aetna Inc. (AET) , and "even some of the higher-quality financial names like Travelers (TRV

Story|11/11/2009

Abbott Labs Leads Drug Stocks Higher

By Val Brickates Kennedy| MarketWatch Pulse| Markets

Val Brickates Kennedy MarketWatch Pulse BOSTON -- Abbott Laboratories led drug stocks into positive territory early Wednesday as shares of the conglomerate gained in the wake of a positive third

Story|10/14/2009

Abbott Beats Estimates, Lifts Forecast

FOXBusiness| Markets

FOXBusiness Shares of Abbott Labs (ABT) rose moderately Tuesday after the drug and diagnostic tool maker reported a third- quarter profit above analysts' estimates

Story|10/14/2009

Abbott Reports 37% Spike In Third-quarter Earnings

By Val Brickates Kennedy| MarketWatch Pulse| Markets

Val Brickates Kennedy MarketWatch Pulse BOSTON -- Abbott Laboratories early Wednesday reported third-quarter net income rose 36.5% to $1.48 billion, or 95 cents a share, compared with $1

Story|10/14/2009

Dow 10000: The Sequel

By Matt Egan| FOXBusiness| Markets

the age of 61, The Wall Street Journal reported ahead of Wednesday's close. Shares of Lazard were halted pending news. Abbott Labs (ABT) reported an adjusted-profit of 92 cents a share on sales of $7.76 billion, topping analysts' views by 2 cents

Story|10/14/2009

Stocks In Focus For Wednesday

By MarketWatch| MarketWatch| Markets

Wednesday's session are J.P. Morgan Chase & Co., Abbott Laboratories and Host Hotels & Resorts Inc. J.P. Morgan Chase ..... according to analysts surveyed by Thomson Reuters. Abbott Laboratories (ABT) is expected to report third-quarter earnings

Story|10/13/2009

Abbott Purchases Solvay Pharma Division

FOXBusiness| Markets

Belgian pharmaceutical company, announced on Monday it is selling its drug-making division to U.S.-based Abbott Laboratories (ABT) for EUR4.5 billion in cash. Solvay plans to use the money raised from the sale to fund its growing

Story|09/28/2009

Drug Stocks Climb; Abbott Gains On Solvay Deal

By Val Brickates Kennedy| MarketWatch Pulse| Markets

Val Brickates Kennedy MarketWatch Pulse BOSTON -- Drug stocks climbed in early action Monday as shares of Abbott Laboratories gained after it announced it was buying Solvay SA's pharmaceutical unit for $6.6 billion, plus future milestone

Story|09/28/2009

«1234»